Abstract
OBJECTIVE
Insulin resistance is a key factor in the pathogenesis of polycystic ovary syndrome (PCOS). Peroxisome proliferator-activated-receptor-γ (PPAR-γ) has been implicated in insulin resistance and adiposity. The aim of the study was to investigate the possible involvement of the Pro12Ala polymorphism of the PPAR-γ gene in the pathogenesis of PCOS.
DESIGN
We studied 180 women with PCOS and 140 healthy controls. Body mass index (BMI) was recorded. Blood samples were drawn after overnight fasting and serum glucose, insulin, lipid and hormonal profiles were determined. The fasting glucose/insulin ratio and HOMA index were calculated. Moreover, 100 women with PCOS underwent a 75g oral glucose tolerance test and the area under the curve for insulin and glucose was estimated. DNA was extracted from peripheral blood leucocytes and the Pro12Ala polymorphism was genotyped.
RESULTS
The PPAR-γ genotypes were found to be in the Hardy-Weinberg equilibrium in both study groups. No difference was found in the distribution of the Pro12Ala polymorphism between PCOS and controls. Insulin resistance indices and lipid and hormonal profile were not different among the various genotypes of the Pro12Ala polymorphism.
CONCLUSIONS
The Pro12Ala polymorphism of the PPAR-γ gene is not involved in the pathogenesis or the phenotypic expression of PCOS.
Similar content being viewed by others
References
Nestler JE, Jacubowitz DJ, 1997 Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens. J Clin Endocrinol Metab 82: 4075–4079.
Corbould A, Kim YB, Youngren JF, et al, 2005 Insulin resistance in the skeletal muscle of women with PCOS involves intrinsic and acquired defects in insulin signaling. Am J Physiol Endocrinol Metab 288: E1047–1054.
Stout DL, Fugate SE, 2005 Thiazolinediones for treatment of polycystic ovary syndrome Pharmacotherapy 25: 244–252.
Deeb SS, Fajas L, Nemoto M, et al, 1998 A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 20: 284–287.
Semple RK, Chatterjee VK, O’Rahilly S, 2006 PPAR gamma and human metabolic disease. J Clin Invest 116: 581–589.
Hara M, Alcoser SY, Qaadir A, Beiswenger KK, Cox NJ, Ehrmann DA, 2002 Insulin resistance is attenuated in women with polycystic ovary syndrome with the Pro12Ala polymorphism in the PPARgamma gene. J Clin Endocrinol Metab 87: 772–775.
Korhonen S, Heinonen S, Hiltunen M, et al, 2003 Polymorphism in the peroxisome proliferator-activated receptor-gamma gene in women with polycystic ovary syndrome. Hum Reprod 18: 540–543.
Orio F Jr, Matarese G, Di Biase S, et al, 2003 Exon 6 and 2 peroxisome proliferator-activated receptor-gamma polymorphisms in polycystic ovary syndrome. J Clin Endocrinol Metab 88: 5887–5892.
Orio F Jr, Palomba S, Cascella T, et al, 2004 Lack of an association between peroxisome proliferator-activated receptor-gamma gene Pro12Ala polymorphism and adiponectin levels in the polycystic ovary syndrome. J Clin Endocrinol Metab 89: 5110–5115.
San Millan JL, Corton M, Villuendas G, Sancho J, Peral B, Escobar-Morreale HF, 2004 Association of the polycystic ovary syndrome with genomic variants related to insulin resistance, type 2 diabetes mellitus, and obesity. J Clin Endocrinol Metab 89: 2640–2646.
Tok EC, Aktas A, Ertunc D, Erdal EM, Dilek S, 2005 Evaluation of glucose metabolism and reproductive hormones in polycystic ovary syndrome on the basis of peroxisome proliferator-activated receptor (PPAR)-gamma2 Pro12Ala genotype. Hum Reprod 20: 1590–1595.
Hahn S, Fingerhut A, Khomtsiv U, et al, 2005 The peroxi-some proliferator activated receptor gamma Pro12Ala polymorphism is associated with a lower hirsutism score and increased insulin sensitivity in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 62: 573–579.
Wang Y, Wu X, Cao Y, Yi L, Fan H, Chen J, 2006 Polymorphisms of the peroxisome proliferator-activated receptor-gamma and its coactivator-1alpha genes in Chinese women with polycystic ovary syndrome. Fertil Steril 85: 1536–1540.
Yilmaz M, Ergun MA, Karakoc A, Yurtcu E, Cakir N, Arslan M, 2006 Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma gene in women with polycystic ovary syndrome. Gynecol Endocrinol 22: 336–342.
Antoine HJ, Pall M, Trader BC, Chen YD, Azziz R, Goodarzi MO, 2007 Genetic variants in peroxisome proliferator-activated receptor gamma influence insulin resistance and testosterone levels in normal women, but not in those with polycystic ovary syndrome. Fertil Steril 87: 862–869.
Zawadzki JK, Dunaif A, 1992 Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In Polycystic ovary syndrome, Dunaif A, Givens JR, Haseltine F, Merriam GR, eds. Boston: Blackwell; pp, 377–84.
Tai M, 1994 A mathematical model for the determination of total area under glucose tolerance and metabolic curves. Diabetes Care 17: 152–154.
Friedewald WT, Levy RI, Fredrickson DS, 1972 Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18: 499–502.
Meirhaeghe A, Cottel D, Amouyel P, Dallongeville J, 2005 Association between peroxisome proliferator-activated receptor gamma haplotypes and the metabolic syndrome in French men and women. Diabetes 54: 3043–3048.
Auwerx J, 1999 PPARgamma, the ultimate thrifty gene. Diabetologia 42: 1033–1049.
Rosen ED, Spiegelman BM, 2001 PPARgamma: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 276: 37731–37734.
Luan J, Browne PO, Harding AH, et al, 2001 Evidence for gene-nutrient interaction at the PPARgamma locus. Diabetes 50: 686–689.
Franks PW, Luan J, Browne PO, et al, 2004 Does peroxi-some proliferator-activated receptor gamma genotype (Pro12Ala) modify the association of physical activity and dietary fat with fasting insulin level? Metabolism 53: 11–16.
Kahara, T, Takamura T, Hayakawa T, et al, 2003 PPAR-gamma gene polymorphism is associated with exercise-mediated changes of insulin resistance in healthy men. Metabolism 52: 209–212.
Mu YM, Yanase T, Nishi Y, et al, 2000 Insulin sensitizer, troglitazone, directly inhibits aromatase activity in human ovarian granulosa cells. Biochem Biophys Res Commun 271: 710–713.
Seto-Young D, Paliou M, Schlosser J, et al, 2005 Direct thiazolidinedione action in the human ovary: insulin-independent and insulin-sensitizing effects on steroidogenesis and insulin-like growth factor binding protein-1 production. J Clin Endocrinol Metab 90: 6099–6105.
Wood JR, Dumesic DA, Abbott DH, Strauss JF 3rd, 2007 Molecular abnormalities in oocytes from women with polycystic ovary syndrome revealed by microarray analysis. J Clin Endocrinol Metab 92: 705–713.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Xita, N., Lazaros, L., Georgiou, I. et al. The Pro12Ala polymorphism of the PPAR-γ gene is not associated with the polycystic ovary syndrome. Hormones 8, 267–272 (2009). https://doi.org/10.1007/BF03401274
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03401274